Role of Insulinlike Growth Factor 1 in Fetal Development and in the Early Postnatal Life of Premature Infants

Abstract

The neonatal period of very preterm infants is often characterized by a difficult adjustment to extrauterine life, with an inadequate nutrient supply and insufficient levels of growth factors, resulting in poor growth and a high morbidity rate. Long-term multisystem complications include cognitive, behavioral, and motor dysfunction as a result of brain damage as well as visual and hearing deficits and metabolic disorders that persist into adulthood. Insulinlike growth factor 1 (IGF-1) is a major regulator of fetal growth and development of most organs especially the central nervous system including the retina. Glucose metabolism in the developing brain is controlled by IGF-1 which also stimulates differentiation and prevents apoptosis. Serum concentrations of IGF-1 decrease to very low levels after very preterm birth and remain low for most of the perinatal development. Strong correlations have been found between low neonatal serum concentrations of IGF-1 and poor brain and retinal growth as well as poor general growth with multiorgan morbidities, such as intraventricular hemorrhage, retinopathy of prematurity, bronchopulmonary dysplasia, and necrotizing enterocolitis. Experimental and clinical studies indicate that early supplementation with IGF-1 can improve growth in catabolic states and reduce brain injury after hypoxic/ischemic events. A multicenter phase II study is currently underway to determine whether intravenous replacement of human recombinant IGF-1 up to normal intrauterine serum concentrations can improve growth and development and reduce prematurity-associated morbidities.

Keywords

fetus - preterm infant - postnatal growth - IGF-1 - metabolism - preterm morbidity

• References

• 1 Laviola L, Natalicchio A, Perrini S, Giorgino F. Abnormalities of IGF-I signaling in the pathogenesis of diseases of the bone, brain, and fetoplacental unit in humans. Am J Physiol Endocrinol Metab 2008; 295 (05) E991-E999
• 2 Ohlsson C, Mohan S, Sjögren K. , et al. The role of liver-derived insulin-like growth factor-I. Endocr Rev 2009; 30 (05) 494-535
• 3 Torres-Aleman I, Villalba M, Nieto-Bona MP. Insulin-like growth factor-I modulation of cerebellar cell populations is developmentally stage-dependent and mediated by specific intracellular pathways. Neuroscience 1998; 83 (02) 321-334
• 4 Rajaram S, Baylink DJ, Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocr Rev 1997; 18 (06) 801-831
• 5 Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev 2002; 23 (06) 824-854
• 6 Verhaeghe J, Van Herck E, Billen J, Moerman P, Van Assche FA, Giudice LC. Regulation of insulin-like growth factor-I and insulin-like growth factor binding protein-1 concentrations in preterm fetuses. Am J Obstet Gynecol 2003; 188 (02) 485-491
• 7 Baumann MU, Schneider H, Malek A. , et al. Regulation of human trophoblast GLUT1 glucose transporter by insulin-like growth factor I (IGF-I). PLoS ONE 2014; 9 (08) e106037
• 8 Hiden U, Glitzner E, Hartmann M, Desoye G. Insulin and the IGF system in the human placenta of normal and diabetic pregnancies. J Anat 2009; 215 (01) 60-68
• 9 Kadakia R, Ma M, Josefson JL. Neonatal adiposity increases with rising cord blood IGF-1 levels. Clin Endocrinol (Oxf) 2016; 85 (01) 70-75
• 10 Han VK, Lund PK, Lee DC, D'Ercole AJ. Expression of somatomedin/insulin-like growth factor messenger ribonucleic acids in the human fetus: identification, characterization, and tissue distribution. J Clin Endocrinol Metab 1988; 66 (02) 422-429
• 11 Bona G, Aquili C, Ravanini P. , et al. Growth hormone, insulin-like growth factor-I and somatostatin in human fetus, newborn, mother plasma and amniotic fluid. Panminerva Med 1994; 36 (01) 5-12
• 12 Netchine I, Azzi S, Le Bouc Y, Savage MO. IGF1 molecular anomalies demonstrate its critical role in fetal, postnatal growth and brain development. Best Pract Res Clin Endocrinol Metab 2011; 25 (01) 181-190
• 13 Hansen-Pupp I, Hellström-Westas L, Cilio CM, Andersson S, Fellman V, Ley D. Inflammation at birth and the insulin-like growth factor system in very preterm infants. Acta Paediatr 2007; 96 (06) 830-836
• 14 Hellström A, Engström E, Hård AL. , et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112 (05) 1016-1020
• 15 Hawdon JM, Ward Platt MP, Aynsley-Green A. Patterns of metabolic adaptation for preterm and term infants in the first neonatal week. Arch Dis Child 1992; 67 (4 Spec No): 357-365
• 16 Hansen-Pupp I, Löfqvist C, Polberger S. , et al. Influence of insulin-like growth factor I and nutrition during phases of postnatal growth in very preterm infants. Pediatr Res 2011; 69 (5 Pt 1): 448-453
• 17 LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 2007; 3 (03) 302-310
• 18 Stigson L, Kistner A, Sigurdsson J. , et al. Bone and fat mass in relation to postnatal levels of insulin-like growth factors in prematurely born children at 4 y of age. Pediatr Res 2014; 75 (04) 544-550
• 19 Bach LA. Endothelial cells and the IGF system. J Mol Endocrinol 2015; 54 (01) R1-R13
• 20 Hellstrom A, Perruzzi C, Ju M. , et al. Low IGF-I suppresses VEGF-survival signaling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci U S A 2001; 98 (10) 5804-5808
• 21 De Paepe ME, Mao Q, Powell J. , et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 2006; 173 (02) 204-211
• 22 Wintermark P, Lechpammer M, Kosaras B, Jensen FE, Warfield SK. Brain Perfusion Is Increased at Term in the White Matter of Very Preterm Newborns and Newborns with Congenital Heart Disease: Does this Reflect Activated Angiogenesis?. Neuropediatrics 2015; 46 (05) 344-351
• 23 Kistner A, Sigurdsson J, Niklasson A, Löfqvist C, Hall K, Hellström A. Neonatal IGF-1/IGFBP-1 axis and retinopathy of prematurity are associated with increased blood pressure in preterm children. Acta Paediatr 2014; 103 (02) 149-156
• 24 Gluckman PD, Harding JE. The physiology and pathophysiology of intrauterine growth retardation. Horm Res 1997; 48 (Suppl. 01) 11-16
• 25 Liu JP, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 1993; 75 (01) 59-72
• 26 Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75 (01) 73-82
• 27 Martin CR, Brown YF, Ehrenkranz RA. , et al; Extremely Low Gestational Age Newborns Study Investigators. Nutritional practices and growth velocity in the first month of life in extremely premature infants. Pediatrics 2009; 124 (02) 649-657
• 28 Ehrenkranz RA, Dusick AM, Vohr BR, Wright LL, Wrage LA, Poole WK. Growth in the neonatal intensive care unit influences neurodevelopmental and growth outcomes of extremely low birth weight infants. Pediatrics 2006; 117 (04) 1253-1261
• 29 Torres-Aleman I. Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol 2010; 70 (05) 384-396
• 30 Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA. Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci U S A 2000; 97 (18) 10236-10241
• 31 Joseph D'Ercole A, Ye P. Expanding the mind: insulin-like growth factor I and brain development. Endocrinology 2008; 149 (12) 5958-5962
• 32 Hansen-Pupp I, Hövel H, Hellström A. , et al. Postnatal decrease in circulating insulin-like growth factor-I and low brain volumes in very preterm infants. J Clin Endocrinol Metab 2011; 96 (04) 1129-1135
• 33 Hansen-Pupp I, Hövel H, Löfqvist C. , et al. Circulatory insulin-like growth factor-I and brain volumes in relation to neurodevelopmental outcome in very preterm infants. Pediatr Res 2013; 74 (05) 564-569
• 34 Blencowe H, Lawn JE, Vazquez T, Fielder A, Gilbert C. Preterm-associated visual impairment and estimates of retinopathy of prematurity at regional and global levels for 2010. Pediatr Res 2013; 74 (Suppl. 01) 35-49
• 35 Löfqvist C, Andersson E, Sigurdsson J. , et al. Longitudinal postnatal weight and insulin-like growth factor I measurements in the prediction of retinopathy of prematurity. Arch Ophthalmol 2006; 124 (12) 1711-1718
• 36 Thébaud B. Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neonatology 2007; 91 (04) 291-297
• 37 Löfqvist C, Hellgren G, Niklasson A, Engström E, Ley D, Hansen-Pupp I. WINROP Consortium. Low postnatal serum IGF-I levels are associated with bronchopulmonary dysplasia (BPD). Acta Paediatr 2012; 101 (12) 1211-1216
• 38 Hellström A, Ley D, Hansen-Pupp I. , et al. Insulin-like growth factor 1 has multisystem effects on foetal and preterm infant development. Acta Paediatr 2016; 105 (06) 576-586
• 39 Yakar S, Liu JL, Fernandez AM. , et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. Diabetes 2001; 50 (05) 1110-1118
• 40 Keswani SG, Balaji S, Katz AB. , et al. Intraplacental gene therapy with Ad-IGF-1 corrects naturally occurring rabbit model of intrauterine growth restriction. Hum Gene Ther 2015; 26 (03) 172-182
• 41 Lassarre C, Hardouin S, Daffos F, Forestier F, Frankenne F, Binoux M. Serum insulin-like growth factors and insulin-like growth factor binding proteins in the human fetus. Relationships with growth in normal subjects and in subjects with intrauterine growth retardation. Pediatr Res 1991; 29 (03) 219-225
• 42 Bang P, Westgren M, Schwander J, Blum WF, Rosenfeld RG, Stangenberg M. Ontogeny of insulin-like growth factor-binding protein-1, -2, and -3: quantitative measurements by radioimmunoassay in human fetal serum. Pediatr Res 1994; 36 (04) 528-536
• 43 Hansen-Pupp I, Engström E, Niklasson A. , et al. Fresh-frozen plasma as a source of exogenous insulin-like growth factor-I in the extremely preterm infant. J Clin Endocrinol Metab 2009; 94 (02) 477-482